Chicago, Illinois GE HealthCare Technologies Inc. (GEHC) designs medical imaging and patient-monitoring products and related equipment and services. Valued at $34.4 billion by market cap, GEHC has a leading share in the imaging and ultrasound equipment market. The company is set to announce its second-quarter results before the market opens on Wednesday, Jul. 30.

Ahead of the event, analysts expect the healthcare major to deliver a profit of $0.91 per share, down 9% from $1 per share reported in the year-ago quarter. On the positive note, the company has a solid earnings surprise history. It has surpassed the Street’s bottom-line estimates in each of the past four quarters.

For the full fiscal 2025, analysts expect GEHC to deliver an EPS of $4.02, down 10.5% from $4.49 reported in the previous year. While in fiscal 2026, its earnings are expected to rebound 12.2% year-over-year to $4.51 per share.

GEHC stock has observed a 1.8% dip over the past 52 weeks, performing slightly better than the Health Care Select Sector SPDR Fund’s (XLV) 6.5% decline, but lagging behind the S&P 500 Index’s ($SPX) 12.3% returns during the same time frame.

GE Healthcare observed a solid start to the year, its stock prices gained 3.3% after the release of its Q1 results on Apr. 30. Driven by strengthening sales in the U.S., the company’s organic revenues observed a notable boost; its overall sales for the quarter grew 2.7% year-over-year to $4.8 billion. Furthermore, driven by the impact of leverage, its adjusted EPS increased 12.2% year-over-year to $1.01, surpassing the consensus estimates by 11%.

The stock holds a consensus “Strong Buy” rating overall. Of the 19 analysts covering the GEHC stock, opinions include 13 “Strong Buys,” one “Moderate Buy,” and five “Holds.” Its mean price target of $87.16 suggests a 15.4% upside potential from current price levels.